Evaluation of Stability and Sterility of Extended Use of Single-use, Preservative-free 0.0015% Tafluprost Eye Drops: An In Vivo Study.

Phase 2

• Conditions: Glaucoma patients; Glaucoma

• Registration Number: TCTR20210224008
• Lead Sponsor: Ratchadapisek Somphot Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-24
• Study Completion: 2022-02-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. > 18 years olds
2. Current use of PGAs eye drop
3. Well-controlled IOP with PGAs eye drop
4. Regular follow-up visit

Exclusion Criteria

1. History of allergy or adverse reaction from PGAs
2. Post trabeculectomy patients
3. Previous ocular surgery within 3 months
4. History of corneal or conjunctival infection
5. Pregnancy and lactation period women

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intraocular pressure Follow up visit (3 months and 6 months) Goldmann applanation tonometry

Secondary Outcome Measures

Name	Time	Method
Corneal or conjunctival infection Every visit Slit lamp examination